CoreOneLabs_LOGO_COL_LRG_300dpi.png
REPEAT – Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer’s Disease
May 06, 2021 09:00 ET | Core One Labs Inc.
VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce that...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer’s Disease
May 06, 2021 03:10 ET | Core One Labs Inc.
VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce that...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
REPEAT - World Renowned Physician Joins Core One Labs as Chief Medical Officer
May 05, 2021 09:00 ET | Core One Labs Inc.
VANCOUVER, British Columbia, May 05, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce it has...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
World Renowned Physician Joins Core One Labs as Chief Medical Officer
May 05, 2021 03:10 ET | Core One Labs Inc.
VANCOUVER, British Columbia, May 05, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce it has...
Vaccinex logo
Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update
March 16, 2021 08:05 ET | Vaccinex, Inc.
Reported top-line results from Phase 2 SIGNAL study that indicates potential cognitive benefit of pepinemab in neurodegenerative disease. New Alzheimer’s study expected to begin enrollment in Q2 ...
Vaccinex logo
Vaccinex to Present at the Oppenheimer 31st Annual Healthcare Conference
March 11, 2021 08:00 ET | Vaccinex, Inc.
ROCHESTER, N.Y., March 11, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
LSU Professor Gartia Receives NSF CAREER Award for Alzheimer’s Research
March 03, 2021 12:20 ET | LSU College of Engineering
BATON ROUGE, La., March 03, 2021 (GLOBE NEWSWIRE) -- LSU Mechanical Engineering Professor Manas Gartia was recently given a National Science Foundation CAREER Award for his project, “Multimodal...
Vaccinex logo
Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology
February 22, 2021 08:30 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex logo
Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform
February 19, 2021 08:00 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
2020-0227 Cognition Logo for GNW.png
Cognition Therapeutics Publishes Biomarker Findings from Clinical Study of CT1812 Supporting Positive Impact on Synapse Biology
February 10, 2021 08:00 ET | Cognition Therapeutics, Inc.
Pittsburgh, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...